NASDAQ:RLMD Relmada Therapeutics (RLMD) Stock Price, News & Analysis $0.60 +0.09 (+17.29%) As of 05/20/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Relmada Therapeutics Stock (NASDAQ:RLMD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Relmada Therapeutics alerts:Sign Up Key Stats Today's Range$0.48▼$0.6150-Day Range$0.25▼$0.7452-Week Range$0.24▼$4.47Volume1.39 million shsAverage Volume917,099 shsMarket Capitalization$19.82 millionP/E RatioN/ADividend YieldN/APrice Target$4.25Consensus RatingHold Company OverviewRelmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.Read More… Relmada Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks81st Percentile Overall ScoreRLMD MarketRank™: Relmada Therapeutics scored higher than 81% of companies evaluated by MarketBeat, and ranked 215th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingRelmada Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageRelmada Therapeutics has received no research coverage in the past 90 days.Read more about Relmada Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Relmada Therapeutics are expected to grow in the coming year, from ($2.73) to ($0.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Relmada Therapeutics is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Relmada Therapeutics is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRelmada Therapeutics has a P/B Ratio of 0.21. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Relmada Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.12% of the outstanding shares of Relmada Therapeutics have been sold short.Short Interest Ratio / Days to CoverRelmada Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Relmada Therapeutics has recently increased by 43.97%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRelmada Therapeutics does not currently pay a dividend.Dividend GrowthRelmada Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.45 Percentage of Shares Shorted6.12% of the outstanding shares of Relmada Therapeutics have been sold short.Short Interest Ratio / Days to CoverRelmada Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Relmada Therapeutics has recently increased by 43.97%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 6 news articles for Relmada Therapeutics this week, compared to 1 article on an average week.Search Interest3 people have searched for RLMD on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Relmada Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Relmada Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $286,332.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders20.70% of the stock of Relmada Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions45.24% of the stock of Relmada Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Relmada Therapeutics' insider trading history. Receive RLMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Relmada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RLMD Stock News HeadlinesRelmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2025 Earnings Call TranscriptMay 14, 2025 | msn.comRelmada Therapeutics, Inc. (RLMD) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.May 21, 2025 | Stansberry Research (Ad)Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 12, 2025 | globenewswire.comRelmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025May 8, 2025 | globenewswire.comRelmada Therapeutics Presents NDV-01 Data at AUA2025 Conference for High-Risk Non-Muscle Invasive Bladder CancerApril 28, 2025 | nasdaq.comRelmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025April 28, 2025 | globenewswire.comRelmada Therapeutics to hold a virtual meetingApril 27, 2025 | markets.businessinsider.comSee More Headlines RLMD Stock Analysis - Frequently Asked Questions How have RLMD shares performed this year? Relmada Therapeutics' stock was trading at $0.52 at the start of the year. Since then, RLMD stock has increased by 14.8% and is now trading at $0.5970. View the best growth stocks for 2025 here. How were Relmada Therapeutics' earnings last quarter? Relmada Therapeutics, Inc. (NASDAQ:RLMD) announced its quarterly earnings results on Monday, May, 12th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.31) by $0.27. Read the conference call transcript. Who are Relmada Therapeutics' major shareholders? Top institutional investors of Relmada Therapeutics include Goldman Sachs Group Inc. (0.36%). Insiders that own company stock include Paul Edward Kelly, Sergio Traversa, Maged Shenouda, Chuck Ence, Charles J Casamento and Cedric O'gorman. View institutional ownership trends. How do I buy shares of Relmada Therapeutics? Shares of RLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Relmada Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Relmada Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), ServiceNow (NOW), GE Aerospace (GE) and Adobe (ADBE). Company Calendar Last Earnings5/12/2025Today5/20/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RLMD CIK1553643 Webwww.relmada.com Phone(786) 629-1376FaxN/AEmployees10Year Founded2004Price Target and Rating Average Stock Price Target$4.25 High Stock Price Target$13.00 Low Stock Price Target$1.00 Potential Upside/Downside+611.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-98,790,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-129.80% Return on Assets-112.06% Debt Debt-to-Equity RatioN/A Current Ratio6.89 Quick Ratio6.89 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.84 per share Price / Book0.21Miscellaneous Outstanding Shares33,192,000Free Float24,743,000Market Cap$19.82 million OptionableOptionable Beta0.18 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:RLMD) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relmada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relmada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.